testosterone testosterone replacement controversial issue despite large number physicians prescribe fda approval products mass marketing number advocates see anti aging performance enhancing drug aging men science behind surprisingly slow era inequities health care often argued race sex seems one science least lags far behind known women expert opinion testosterone replacement changed little years despite much popular literature occurred years europe widespread benefit physical emotional well men age clinical perspective psychiatrists seeing middle aged men testosterone replacement treatment modality significant implications medical treatment provided psychiatrists well associated comorbidity psychiatric perspective also important determine testosterone use indicated associated increasing muscle mass body image changes occurring context unreasonable expectations like preserving youth reversing effects aging athletic performance enhancement recent study men years age older authors examined effects treatment testosterone gel period one year total number subjects total men screened order qualify trial testosterone level sufficiently low less ng dl one two samples eliminated screened men trial designed look physical function sexual function vitality treatment resulted testosterone levels mid normal range year old men despite considerable medical comorbidity recruited patients clear cutoffs medical comorbidity cutoffs included history prostate cancer risk prostate cancer prostate cancer risk calculator conditions known cause hypogonadism medications known effect concentration testosterone high cardiovascular severe depression phq score overall results showed moderate benefit sexual functioning benefit mood depressive symptoms effect physical functioning vitality look measurements instructive physical function assessed using minute walk recent normative data established various age cohorts using subjects several countries data establishes normative curves age cohort stratified sex six minute walk distance mwd ranged meters year old men meters year old men two trials subjects usually walked average meter farther second trial present study criterion positive effects testosterone walking distance increase meters compared controls testosterone treated men significantly men increasing distance walked meters percentage men exceeding measure change baseline percentage men higher scores physical function domain test pf medical outcomes study item short form instrument sf one concerns i reading methodology use testosterone physical performance enhancement effective without using training program subjects study advised extend walking distances speed without i skeptical would much effect vitality determined measures facit fatigue score primary outcome measure interestingly facit stands functional assessment cancer treatment web page links extensive list modified rating scales i could tell rating scale validated normal year old men without cancer diagnosis significant differences noted testosterone treated men controls secondary measures testosterone treated men likely report higher energy end trial measure unspecified may line item sf sexual function measured primarily question psychosexual daily questionnaire item item yes checklist male sexual behaviors thoughts fantasies greater testosterone levels achieved treatment correlated higher testosterone levels secondary measure derogatis interview sexual functioning men ii disf ii also documented increased sexual desire also used screen participants sexual function arm trial sexual function measures appear straightforward self report measures considerable time frames one interesting aspects trial analysis side effects one main concerns treating men testosterone risk prostate cancer sensitive testosterone levels i personal communication physicians treating patients testosterone developed widely metastatic prostate cancer significant adverse effects trial summarized table placebo treated men compared testosterone treated men events summarized according prostate specific antigen psa level increases diagnoses prostate cancer elevations hemoglobin myocardial infarction stroke cause cardiovascular death death hospitalization although greater number psa elevations testosterone treated men case prostate cancer compared controls year study cases prostate cancer testosterone group one placebo group subsequent year study rationale study try add results previous trials showed inconsistent results testosterone replacement muscle mass body fat sexual function energy level physical function disappointing read details find much effect methodology st century weak good news i find article relatively safe replace testosterone year old men rigorously screened hypogonadism prostate cancer risk although selection bias project like certainly consideration i asked myself whether men self selected replacement low testosterone ads would rejected level physicians course researchers point risk long run determined larger trials opinion post marketing surveillance post marketing surveillance suggested fda really blunt instrument compared type organized pharmacosurveillance screening new cases prostate cancer particular electronic health record testosterone prescriptions level i wonder research questions would answered completely trials focused solely groups large number investigators many investigators appearance conflict interest affiliations pharmaceutical companies many results study consistent clinical psychiatrists see practice uncommon see men taking supraphysiological doses testosterone wanting reduce doses common see men testosterone stop taking clear efficacy concerned women girls life accidentally come contact testosterone let face really hypoandrogenism fueling debate i advocate aging gracefully accepting happens i think dieting exercising first years life would useful medical science could provide something help maintain active lifestyle prevent kind morbidity slows leads deconditioning host metabolic factors hasten aging death preventing pathway physical deterioration depends maintaining attitude muscle joints bone another paper documenting clear solution array problems unfortunate medicine scientific solution point even hearing unscientific hype testosterone growth hormone past years george dawson md dlfapa references snyder pj bhasin cunningham gr matsumoto stephens shields aj cauley ja gill tm barrett connor swerdloff rs wang ensrud ke lewis farrar jt cella rosen rc pahor crandall jp molitch me cifelli dougar fluharty l resnick sm storer tw anton basaria diem sj hou mohler er rd parsons jk wenger nk zeldow landis jr ellenberg ss testosterone trials investigators effects testosterone treatment older men engl med feb doi nejmoa pubmed pmid casanova celli br barria p casas cote de torres jp jardim lopezmv marin jm montes de oca pinto plata v aguirre jaime six minute walk distance project alat min walk distance healthy subjects reference standards seven countries eur respir jan pubmed pmid lee kk berman alexander gm hull l swerdloff rs wang simple self report diary assessing psychosexual function hypogonadal men androl sep oct pubmed pmid brief video two minute nejm video summarizing trial found link interestingly video attributes sexual function vitality physical function testosterone decrease age yet full replacement point equivalent levels much younger men nothing physical function vitality